What laboratory workup is recommended to evaluate and screen a patient with rheumatoid arthritis before initiating disease‑modifying therapy, including baseline labs, serologic tests, infection screening, pregnancy testing, HLA‑B27, and baseline chest imaging?

Laboratory Workup for Rheumatoid Arthritis Before Initiating DMARD Therapy

Before starting disease-modifying therapy for rheumatoid arthritis, you must obtain: RF and/or ACPA, ESR, CRP, complete blood count with differential, comprehensive metabolic panel (hepatic and renal function), and screening for hepatitis B, hepatitis C, and tuberculosis. 1 Additional baseline imaging of hands and feet is strongly recommended. 1

Essential Serologic Tests

Autoantibody Testing

• Rheumatoid Factor (RF) and Anti-Citrullinated Protein Antibodies (ACPA) are mandatory—these predict both RA diagnosis and prognosis, including risk of persistent synovitis and radiographic progression 1
• Negative RF or ACPA does not exclude RA progression, so clinical judgment remains paramount 1
• If connective tissue disease is suspected based on clinical features, add ANA and antibodies to extractable nuclear antigens 1

Inflammatory Markers

• ESR and CRP should be obtained at baseline 1
• While CRP alone is a poor predictor of persistent arthritis, elevated levels (especially when high) support RA diagnosis 1
• These markers guide treatment monitoring but have limited prognostic value for structural damage 1

Baseline Laboratory Panel

Complete Blood Count and Chemistry

• CBC with differential: Essential to establish baseline before DMARD therapy and detect cytopenias 2
• Comprehensive metabolic panel: Assess hepatic function (AST, ALT) and renal function (creatinine/eGFR) before initiating methotrexate or other DMARDs 1, 2
• Consider glucose and urate levels as part of comprehensive assessment 1

Mandatory Infection Screening Before DMARD Initiation

This is non-negotiable and must be completed before starting any DMARD, particularly biologic agents:

• Hepatitis B and C screening 3, 4, 3, 4, 3, 2
• Tuberculosis testing (either tuberculin skin test or interferon-gamma release assay) 3, 4, 3, 4, 3, 2

The evidence from multiple ASCO guidelines consistently emphasizes this screening before DMARD treatment to prevent reactivation of latent infections 3.

Baseline Imaging

Radiographic Assessment

• X-rays of hands, wrists, and feet should be performed at baseline 1
• Presence of erosions predicts RA development and disease persistence 1
• Repeat imaging within 1 year to assess progression 1
• X-rays of other affected joints should be obtained as clinically indicated 1

Special Considerations

HLA-B27 Testing

HLA-B27 is NOT routinely indicated for rheumatoid arthritis workup. 1 This test is relevant only if:

• Axial or entheseal involvement suggests spondyloarthropathy rather than RA 1
• Clinical features point toward reactive arthritis or ankylosing spondylitis 4

The evidence shows HLA-B27 testing is frequently overused and should be reserved for suspected spondyloarthritis, not RA 5.

Pregnancy Testing

While not explicitly mentioned in RA-specific guidelines, pregnancy testing is mandatory in women of childbearing potential before initiating methotrexate or other teratogenic DMARDs, as this is standard of care in rheumatology practice.

Chest Imaging

Baseline chest X-ray should be obtained before DMARD therapy to:

• Screen for latent tuberculosis (in conjunction with TB testing)
• Establish baseline for potential methotrexate-related pulmonary toxicity monitoring
• Detect pre-existing interstitial lung disease

Monitoring After DMARD Initiation

Once therapy begins, laboratory monitoring intensity is highest in the first 4 months:

• Weeks 2 and 4: CBC, hepatic function, renal function 6
• Monthly for first 4 months: Same parameters 6
• After 4 months: 2-4 times per year 6

This schedule detects 98.3% of laboratory abnormalities in a timely manner and reduces costs by up to 78% compared to more frequent monitoring 6.

Common Pitfalls to Avoid

1. Do not order HLA-B27 reflexively—it has no role in typical RA diagnosis and leads to unnecessary costs and confusion 5

2. Do not skip infection screening—reactivation of hepatitis B or tuberculosis during immunosuppression can be fatal 3

3. Do not delay DMARD therapy waiting for "complete" autoantibody panels—RF and ACPA are sufficient; additional autoantibodies are only needed if clinical features suggest overlap syndromes 1

4. Do not over-monitor after the first 4 months—laboratory abnormalities from DMARDs occur early, and excessive testing wastes resources without improving safety 6